Cytokinetics (CYTK) AI Stock Analysis

• Market Cap: $8.03B
• Dividend Yield: N/A
• Average Volume (3M): 1.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: 2609.26%
• EPS Growth: -17.08%
• Country: US
• Employees: 498
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.55
• Shares Outstanding: 122,264,930
• 10 Day Avg. Volume: 1,508,978
• 30 Day Avg. Volume: 1,781,375
• PEG Ratio: 2.56
• Price to Book (P/B): -38.91
• Price to Sales (P/S): 285.13
• P/FCF Ratio: -13.18
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 78.26
• Enterprise Value/Gross Profit: -61.37
• Enterprise Value/Ebitda: -10.56
• 1Y Price Target: $81.50
• Price Target Upside: 24.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -6.32
• Revenue Forecast (FY): $83.29M

• Rating: 58 Neutral
• Price Target: $69.00 ▲(5.07% Upside)

Cytokinetics' overall stock score reflects significant financial challenges and valuation concerns, partially offset by positive technical indicators and strategic progress towards drug approvals. The earnings call and corporate events provide optimism for future growth, but financial instability remains a critical risk.

Positive Factors

Strong Financial Position

A robust cash position provides Cytokinetics with the financial flexibility to invest in R&D and commercialization efforts, supporting long-term growth.

MAPLE-HCM Trial Success

Successful trial results enhance the credibility and market potential of aficamten, positioning it as a superior treatment option in the oHCM market.

Leadership Enhancement

Strengthening the leadership team with experienced personnel can improve strategic decision-making and regulatory compliance, aiding long-term stability.

Negative Factors

Increased Net Loss

Rising net losses indicate ongoing financial challenges, which may limit the company's ability to invest in growth initiatives and affect long-term viability.

High Leverage

High leverage and negative equity pose risks to financial stability, potentially impacting the company's ability to meet debt obligations and fund operations.

Pending Regulatory Approvals

Pending regulatory approvals introduce uncertainty and delay potential revenue streams, affecting market confidence and strategic planning.

Cytokinetics Business Overview & Revenue Model

Company Description

Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics to treat debilitating diseases in the fields of muscle biology and neuromuscular function. The company operates primarily in the biotechnology sector and is dedicated to advancing innovative treatments for heart failure, cancer, and other conditions that affect muscle strength and function. Its core products include various drug candidates targeting muscle contractility and function, with a strong emphasis on addressing unmet medical needs in the cardiovascular and neuromuscular arenas.

How the Company Makes Money

Cytokinetics generates revenue primarily through the development of its drug candidates, which may include licensing agreements, collaboration deals, and partnerships with larger pharmaceutical companies. The company may receive milestone payments and royalties from these collaborations, particularly if their clinical trials lead to successful product approvals. Additionally, Cytokinetics may generate revenue through grants and government funding for research and development. The company's financial performance is closely tied to the progress of its clinical trials and the commercialization of its therapeutic products.

Cytokinetics Financial Statement Overview

Summary

Cytokinetics faces significant financial challenges, with negative profitability and high leverage. Despite revenue growth, the company struggles with high costs and negative cash flows, indicating financial instability.

Income Statement

Cytokinetics has experienced significant revenue growth in recent periods, but it remains unprofitable with negative margins across the board. The gross profit margin and net profit margin are deeply negative, indicating high costs relative to revenue. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a concerning level of leverage, with a negative debt-to-equity ratio due to negative stockholders' equity. This indicates financial instability and potential risk in meeting debt obligations. The return on equity is positive but misleading due to negative equity, and the equity ratio is not favorable.

Cash Flow

Cytokinetics has negative operating and free cash flows, although there is some growth in free cash flow. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	87.21M	18.47M	7.53M	94.59M	70.43M	55.83M
Gross Profit	-111.22M	-320.93M	-322.59M	-146.22M	-89.51M	-41.12M
EBITDA	-646.17M	-493.48M	-456.68M	-329.40M	-176.34M	-86.78M
Net Income	-751.94M	-589.53M	-526.24M	-388.95M	-215.31M	-127.29M
Balance Sheet
Total Assets	1.44B	1.40B	824.32M	1.01B	841.32M	533.80M
Cash, Cash Equivalents and Short-Term Investments	962.53M	1.08B	614.82M	782.58M	471.64M	464.06M
Total Debt	1.20B	788.68M	755.77M	750.30M	269.93M	138.94M
Total Liabilities	1.96B	1.54B	1.21B	1.12B	597.46M	420.42M
Stockholders Equity	-521.12M	-135.37M	-386.32M	-107.90M	243.86M	113.38M
Cash Flow
Free Cash Flow	-453.38M	-399.80M	-415.75M	-310.85M	-191.39M	-2.11M
Operating Cash Flow	-432.93M	-395.89M	-414.33M	-299.52M	-142.52M	8.94M
Investing Cash Flow	198.72M	-553.10M	239.25M	-262.13M	-147.78M	-196.51M
Financing Cash Flow	416.14M	930.61M	221.32M	516.17M	319.98M	234.12M

Cytokinetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTK, the sentiment is Positive. The current price of 65.67 is above the 20-day moving average (MA) of 65.55, above the 50-day MA of 61.57, and above the 200-day MA of 44.58, indicating a bullish trend. The MACD of 1.46 indicates Positive momentum. The RSI at 54.74 is Neutral, neither overbought nor oversold. The STOCH value of 45.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYTK.

Cytokinetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RNA	62 Neutral	$10.79B	―	-32.44%	―	106.27%	-43.90%
CYTK	58 Neutral	$8.03B	―	―	―	2609.26%	-17.08%
AXSM	57 Neutral	$7.52B	―	-275.50%	―	65.83%	28.50%
RYTM	52 Neutral	$6.98B	-33.71	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	47 Neutral	$5.20B	―	-22.60%	―	74.91%	31.54%
NUVL	43 Neutral	$7.97B	―	-38.79%	―	―	-52.84%

Cytokinetics Corporate Events

Cytokinetics Appoints New Executive VP and CLO

On November 13, 2025, Cytokinetics announced the appointment of Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025. Mr. Hessekiel brings extensive legal and compliance experience from his previous roles at Exelixis, Arnold & Porter LLP, and Gilead Sciences, Inc. His compensation package includes a base salary of $660,000, a signing bonus, and an equity award, reflecting the company’s strategic focus on strengthening its leadership team to enhance its market position.

Cytokinetics Discusses Aficamten with FDA in Late Cycle Meeting

On September 15, 2025, Cytokinetics participated in a Late Cycle Meeting with the FDA regarding its New Drug Application for aficamten, aimed at treating obstructive hypertrophic cardiomyopathy. The company discussed its Risk Evaluation and Mitigation Strategies (REMS) and anticipates a differentiated label for aficamten, pending FDA approval by December 26, 2025. Additionally, Cytokinetics responded to the European Medicines Agency’s questions about aficamten’s potential EU approval. The company plans to draw $100 million from a loan agreement with Royalty Pharma by October 1, 2025, to support its development efforts.